Canadian cannabis company CannTrust Holdings Inc (TSX:TRST) said on Friday the its Danish Joint Venture Partner STENOCARE has announced the receipt of approval to distribute CannTrust products in Denmark.

According to CannTrust, its high-quality, standardised cannabis oils are the first oils approved for Denmark's list of admitted cannabis products and are the only "ready-to-use" oil products available.

On 1 January 2018, the medical cannabis became legal in Denmark after a unanimous vote by the Country's parliament. Danish rules surrounding the production of medical cannabis require a high degree of purity and quality, making CannTrust a natural partner for STENOCARE. STENOCARE now has a unique opportunity to set the industry standard for practitioners and patients.

In conjunction, STENOCARE, a first-mover in Denmark's legalization of medical cannabis, has supply agreements with two of Denmark's leading pharmaceutical distributors, who together service 99% of pharmacies in the country.

STENOCARE will initially sell CannTrust's cannabis oils while working towards the construction of a domestic growing facility, with technical expertise being provided by CannTrust. CannTrust received a 25% equity stake in Steno Investments IVS together with the right to appoint half of its board of directors.